Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB treatment news

Show

From To
TB treatment
Will a new TB treatment be available soon?

Experts advising the U.S. Food and Drug Administration on marketed and investigational drugs for infectious diseases and disorders were divided on whether the regulatory agency should approve a new drug as part of a proposed combination therapy for highly resistant tuberculosis. The majority of the independent experts — 14 out of 18 — advising the regulatory agency voted favorably last month. But the remaining four found insufficient evidence on efficacy and safety of the TB Alliance’s oral anti-TB drug pretomanid when used in combination with bedaquiline and linezolid, or BPaL.

Published
08 July 2019
From
Devex
Pharmaceutical industry
Will new TB treatments reach those who need them most?

Pharma giant GlaxoSmithKline is pursuing new treatments for tuberculosis but insists it will need support from governments and funding agencies if it is to get them to patients in lower-income countries, the head of its global health unit, David Barros-Aguirre, told Devex.

Published
15 April 2019
From
Devex
Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.


Published
12 March 2019
From
HIV i-Base
TB treatment
Pulmonary TB can be cured with shorter treatment, study finds

New data analysis uses precision medicine approach to demonstrate treatment efficacy. When patients were retrospectively stratified into minimal, moderate and severe disease categories, the four-month drug regimens turned out to have been highly effective for the 47 percent of patients with minimal disease. But the four-month regimens were not effective for patients with moderate or severe disease. And even the standard six-month treatment was insufficient for those with the most extensive disease.

Published
06 November 2018
From
Eurekalert Inf Dis
TB treatment
Ending tuberculosis will take lower drug prices and a new, improved innovation ecosystem

Prisha and millions of other people with tuberculosis and drug-resistant tuberculosis do not need more patents for drugs they can’t afford. Instead, they need a better system with new incentives. They need real innovation. And right now they need a political declaration from the U.N.’s high-level meeting on tuberculosis that reaffirms countries’ legal right to use TRIPS flexibilities when they cannot otherwise afford the lifesaving treatments that Prisha and millions like her desperately need.

Published
13 September 2018
From
STAT
TB treatment
SimpliciTB Clinical Trial Launched with First Patients in Tbilisi, Georgia

New pivotal trial examines potential of BPaMZ regimen to shorten treatment for tuberculosis and multidrug-resistant tuberculosis.

Published
28 August 2018
From
TB Alliance
TB treatment
How smartphones are becoming a weapon in the global fight against tuberculosis

Mobile technologies devised by researchers at the University of California, San Diego, and Johns Hopkins are allowing patients to use their phones to record daily medication intake. The encrypted videos are sent to public health workers who can watch them from their cubicles, instead of traveling long distances every day to visit patients at their homes or workplaces.

Published
21 August 2018
From
STAT
TB treatment
South Africa strikes deal on new TB drug as WHO revisits guidance

The World Health Organization could soon start promoting a new tuberculosis drug that is now more affordable after South Africa brokered a deal with a pharmaceutical company to slash the price by half.

Published
13 August 2018
From
Devex
TB treatment
AIDS 2018: Price of bedaquiline drops in South Africa, will replace injectable TB drugs, Minister of Health announces

South Africa has signed a deal with bedaquiline manufacturer Jannsen pharmaceuticals to drop the price of the drug from $750 for a full course to $400, for the next eight months,Minister of Health Aaron Motsoaledi announced here today.

Published
23 July 2018
From
Science Speaks
TB treatment
Higher doses of rifampin appear more effective in fighting TB without increasing risk of adverse events

Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Published
29 June 2018
From
Eurekalert Inf Dis
← First12345...13Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.